A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
In this section, unless otherwise specified, references to “we,” “our,” “us” and “our company” refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (“Gyre Pharmaceuticals”). We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California. In the PRC, we have established a strong commercial and operational foundation in fibrotic diseases through the successful development and commercialization of ETUARY® (pirfenidone), which has generated consistent revenue and positioned us as a leading participant in the treatment of pulmonary fibrosis.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 117M | 117M | 106M | 113M | 102M | - |
| Net Income | 5.0M | 5.0M | 12M | -93M | -8.2M | -88M |
| EPS | $0.02 | $0.02 | $0.05 | $-1.41 | $-3.90 | $-43.05 |
| Free Cash Flow | -180K | -180K | -6.0M | 17M | -38M | -85M |
| ROIC | 8.6% | 17.2% | 32.6% | -57.7% | 13.0% | -124.7% |
| Gross Margin | 43.1% | 43.1% | 51.5% | 95.9% | 44.1% | - |
| Debt/Equity | 0.01 | 0.01 | 0.03 | -0.03 | 0.01 | 0.06 |
| Dividends/Share | $0.00 | - | - | - | $3.60 | - |
| Operating Income | 11M | 11M | 16M | -67M | 9.2M | -88M |
| Operating Margin | 9.9% | 9.9% | 15.3% | -59.3% | 9.0% | - |
| ROE | 4.7% | 5.9% | 19.1% | - | -19.4% | -214.0% |
| Shares Outstanding | 97M | 97M | 97M | 66M | 6M | 2M |
GYRE THERAPEUTICS, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
GYRE THERAPEUTICS, INC. trades at 192.3x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 255.8x vs a median of 99.7x. The company's 5-year average gross margin is 58.6%. At current prices, the estimated annualized return to fair value is -5.4%.
GYRE THERAPEUTICS, INC. (GYRE) has a current P/E ratio of 192.3, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
GYRE THERAPEUTICS, INC. (GYRE) has a 5-year average return on invested capital (ROIC) of -23.9%. This is below average and may indicate limited pricing power.
GYRE THERAPEUTICS, INC. (GYRE) has a market capitalization of $746M. It is classified as a small-cap stock.
GYRE THERAPEUTICS, INC. (GYRE) does not currently pay a regular dividend.
Based on historical P/E analysis, GYRE THERAPEUTICS, INC. (GYRE) appears expensive. The current P/E of 192.3 is 1182% above its historical median of 15.0. The estimated fair value CAGR (P/E method) is -22.4%.
GYRE THERAPEUTICS, INC. (GYRE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
GYRE THERAPEUTICS, INC. (GYRE) reported annual revenue of $117 million in its most recent fiscal year, based on SEC EDGAR filings.
GYRE THERAPEUTICS, INC. (GYRE) has a net profit margin of 4.3%. This is a modest margin.
GYRE THERAPEUTICS, INC. (GYRE) generated $-180 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
GYRE THERAPEUTICS, INC. (GYRE) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
GYRE THERAPEUTICS, INC. (GYRE) reported earnings per share (EPS) of $0.02 in its most recent fiscal year.
GYRE THERAPEUTICS, INC. (GYRE) has a return on equity (ROE) of 5.9%. This indicates moderate shareholder returns.
GYRE THERAPEUTICS, INC. (GYRE) has a 5-year average gross margin of 58.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for GYRE THERAPEUTICS, INC. (GYRE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GYRE THERAPEUTICS, INC. (GYRE) has a book value per share of $1.09, based on its most recent annual SEC filing.